 Aduro Biotech, Inc. ADRO, a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes STING and A Proliferation Inducing Ligand APRIL pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced the presentation of healthy volunteer data from the ongoing Phase 1 study of BION-1301 for the treatment of IgA nephropathy as well as data from long-term nonclinical studies. The findings are being presented as posters at the 57th European Renal Association European Dialysis and Transplant Association ERA-EDTA Fully Virtual Congress. 